Nivaquine, tablets containing chloroquine and Plaqueril, tablets containing hydroxychloroquine have shown signs of effectiveness against coronavirus, French doctors think. Picture: GERARD JULIEN. PHOENIX, ARIZONA (REUTERS) - An Arizona man has died and his wife is in critical condition after they ingested chloroquine phosphate - an aquarium cleaning product similar to drugs that have been.
Key:WHTVZRBIWZFKQO-UHFFFAOYSA-N YChloroquine is a medication primarily used to prevent and treat in areas where malaria remains sensitive to its effects. Certain types of malaria, resistant strains, and complicated cases typically require different or additional medication. Chloroquine is also occasionally used for that is occurring outside the intestines,. While it has not been formally studied in pregnancy, it appears safe.
It is also being studied to treat as of 2020. It is taken by mouth.Common side effects include muscle problems, loss of appetite, diarrhea, and skin rash. Serious side effects include problems with vision, muscle damage,. Chloroquine is a member of the drug class. As an antimalarial, it works against the asexual form of the in the stage of its life cycle within the.
How it works in rheumatoid arthritis and lupus erythematosus is unclear.Chloroquine was discovered in 1934. It is on the, the safest and most effective medicines needed in a. It is available as a. The wholesale cost in the is about US$0.04. In the, it costs about US$5.30 per dose.
Distribution of malaria in the world:♦ Elevated occurrence of chloroquine- or multi-resistant malaria♦ Occurrence of chloroquine-resistant malaria♦ No Plasmodium falciparum or chloroquine-resistance♦ No malariaChloroquine has been used in the treatment and prevention of from,. It is generally not used for as there is widespread resistance to it.Chloroquine has been extensively used in, which may have contributed to the emergence and spread of resistance. It is recommended to check if chloroquine is still effective in the region prior to using it. In areas where resistance is present, other, such as or, may be used instead. The recommend against treatment of malaria with chloroquine alone due to more effective combinations. AmebiasisIn treatment of, chloroquine may be used instead of or in addition to other medications in the event of failure of improvement with or another within 5 days or intolerance to metronidazole or a nitroimidazole. Rheumatic diseaseAs it mildly suppresses the, chloroquine is used in some, such as.
Formation in P. Falciparum: many antimalarials are strong inhibitors of hemozoin crystal growth.The lysosomotropic character of chloroquine is believed to account for much of its antimalarial activity; the drug concentrates in the acidic food vacuole of the parasite and interferes with essential processes. Its lysosomotropic properties further allow for its use for in vitro experiments pertaining to intracellular lipid related diseases, autophagy, and apoptosis.Inside, the malarial, which is then in its asexual stage, must degrade to acquire essential amino acids, which the parasite requires to construct its own protein and for energy metabolism.
Digestion is carried out in a vacuole of the parasitic cell. Hemoglobin is composed of a protein unit (digested by the parasite) and a heme unit (not used by the parasite). During this process, the parasite releases the toxic and soluble molecule. The heme moiety consists of a porphyrin ring called Fe(II)-protoporphyrin IX (FP).
To avoid destruction by this molecule, the parasite biocrystallizes heme to form, a nontoxic molecule. Hemozoin collects in the digestive vacuole as insoluble crystals. Chloroquine enters the red blood cell by simple diffusion, inhibiting the parasite cell and digestive vacuole.
Chloroquine then becomes protonated (to CQ2+), as the digestive vacuole is known to be acidic (pH 4.7); chloroquine then cannot leave by diffusion. Chloroquine caps hemozoin molecules to prevent further of heme, thus leading to heme buildup. Chloroquine binds to heme (or FP) to form the FP-chloroquine complex; this complex is highly toxic to the cell and disrupts membrane function. Action of the toxic FP-chloroquine and FP results in cell lysis and ultimately parasite cell autodigestion.
Parasites that do not form hemozoin are therefore resistant to chloroquine. Resistance in malariaSince the first documentation of P.
Falciparum chloroquine resistance in the 1950s, resistant strains have appeared throughout East and West Africa, Southeast Asia, and South America. The effectiveness of chloroquine against P. Falciparum has declined as resistant strains of the parasite evolved. They effectively neutralize the drug via a mechanism that drains chloroquine away from the digestive vacuole. Chloroquine-resistant cells efflux chloroquine at 40 times the rate of chloroquine-sensitive cells; the related mutations trace back to transmembrane proteins of the digestive vacuole, including sets of critical mutations in the P.
Falciparum chloroquine resistance transporter ( PfCRT) gene. The mutated protein, but not the wild-type transporter, transports chloroquine when expressed in oocytes (frog's eggs) and is thought to mediate chloroquine leak from its site of action in the digestive vacuole. Resistant parasites also frequently have mutated products of the P. Falciparum multidrug resistance ( PfMDR1) gene, although these mutations are thought to be of secondary importance compared to Pfcrt., a Ca 2+ channel blocker, has been found to restore both the chloroquine concentration ability and sensitivity to this drug. Recently, an altered chloroquine-transporter protein CG2 of the parasite has been related to chloroquine resistance, but other mechanisms of resistance also appear to be involved.
Research on the mechanism of chloroquine and how the parasite has acquired chloroquine resistance is still ongoing, as other mechanisms of resistance are likely. Other agents which have been shown to reverse chloroquine resistance in malaria are,. AntiviralChloroquine has effects.
It increases late endosomal and lysosomal pH, resulting in impaired release of the virus from the endosome or lysosome – release of the virus requires a low pH. The virus is therefore unable to release its genetic material into the cell and replicate.Chloroquine also seems to act as a zinc ionophore, that allows extracellular zinc to enter the cell and inhibit viral RNA-dependent. OtherChloroquine inhibits uptake. It acts specifically on the transporter.Against, it operates by inhibiting proliferation, antigen presentation in dendritic cells, release of from, release of from, and production of.HistoryIn, the indigenous people extracted the bark of the tree ( ) and used the extract to fight chills and fever in the seventeenth century.
In 1633 this herbal medicine was introduced in Europe, where it was given the same use and also began to be used against malaria. The quinoline antimalarial drug was isolated from the extract in 1820, and chloroquine is an analogue of this.Chloroquine was discovered in 1934, by and coworkers at the laboratories, who named it Resochin. It was ignored for a decade, because it was considered too toxic for human use.
Instead, the used the chloroquine analogue 3-methyl-chloroquine, known as Sontochin. After Allied forces arrived in Tunis, Sontochin fell into the hands of Americans, who sent the material back to the United States for analysis, leading to renewed interest in chloroquine. United States government-sponsored clinical trials for antimalarial drug development showed unequivocally that chloroquine has a significant therapeutic value as an antimalarial drug. It was introduced into clinical practice in 1947 for the prophylactic treatment of malaria. Society and culture. See also:, andAs of 8 April 2020, there is limited evidence to support the use of chloroquine in treating.
In January 2020, during the, Chinese medical researchers stated that into chloroquine seemed to have 'fairly good inhibitory effects' on the virus. Requests to start clinical testing were submitted. Use, however, is only recommended in the setting of an approved trial or under the details outlined by.Chloroquine has been approved by Chinese, South Korean and Italian health authorities for the experimental treatment of COVID-19. These agencies noted for people with or.Health experts warned against the misuse of the non-pharmaceutical versions of chloroquine phosphate after a husband and wife consumed a fish tank containing chloroquine phosphate on March 24, with the intention of it being against COVID-19. One of them died and the other was hospitalized. Chloroquine has a relatively narrow and it can be toxic at levels not much higher than those used for treatment—which raises the risk of inadvertent overdose. On 27 March 2020, the US (FDA) issued guidance, 'do not use chloroquine phosphate intended for fish as treatment for COVID-19 in humans'.On March 28, 2020 the FDA authorized the use of and chloroquine under an (EUA).
The treatment has not been approved by the FDA. The experimental treatment is authorized only for emergency use for people who are hospitalized but not able to receive treatment in a clinical trial.On 1 April 2020, the (EMA) issued guidance that chloroquine and hydroxychloroquine are only to be used in clinical trials or emergency use programs.A study of chloroquine in 81 hospitalized people in Brazil was halted. About 40 people with coronavirus got a 600 milligram dose over 10 days. By the sixth day of treatment, 11 of them had died, leading to an immediate end to the high-dose segment of the trial. About 40 other people received a dose of 450 milligrams of chloroquine twice daily for five days.In anticipation of product shortages, the FDA issued product-specific guidance for chloroquine phosphate and for hydroxychloroquine sulfate for generic drug manufacturers. Other virusesChloroquine had been also proposed as a treatment for, with tests inhibiting the virus.
In October 2004, a group of researchers at the Rega Institute for Medical Research published a report on chloroquine, stating that chloroquine acts as an effective inhibitor of the replication of the severe acute respiratory syndrome coronavirus in vitro.Chloroquine was being considered in 2003, in pre-clinical models as a potential agent against fever. OtherThe and properties of chloroquine are beginning to be exploited in anticancer strategies in humans. In, chloroquine is used for experiments to inhibit degradation of protein products.References.
Comments are closed.
|
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
March 2023
Categories |